CN Patent

CN117098760B — 用于治疗kit和pdgfra介导的疾病的组合物和方法

Assigned to Cable Chart Pharmaceutical Co · Expires 2026-04-14 · 0y expired

What this patent protects

本公开提供式(I‑0)的化合物， 其药用盐、和/或前述任一项的溶剂化物，其用于治疗与突变KIT和PDGFRα相关的疾病和病症，并且呈现用于治疗与突变KIT和PDGFRα相关的疾病和病症的有利的非脑渗透特性。本公开还提供了用于治疗胃肠道间质瘤和系统性肥大细胞增多症的方法。

USPTO Abstract

本公开提供式(I‑0)的化合物， 其药用盐、和/或前述任一项的溶剂化物，其用于治疗与突变KIT和PDGFRα相关的疾病和病症，并且呈现用于治疗与突变KIT和PDGFRα相关的疾病和病症的有利的非脑渗透特性。本公开还提供了用于治疗胃肠道间质瘤和系统性肥大细胞增多症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117098760B
Jurisdiction
CN
Classification
—
Expires
2026-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Cable Chart Pharmaceutical Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.